Bicurion Therapeutics AB - Research and development on exosomes for immunological treatment of solid tumors

Bicurion is a subsidiary of Exocure Sweden AB that does research and development on exosomes and works in a targeted manner on immunological treatment of solid tumors, e.g. melanoma in the initial phase. By using a lower dose that is delivered via exosomes to the right target, new drugs can be developed. 

Impact: This can lead to highly effective treatments with fewer side effects and can lead to better health for more people. 

CEO: Sören Mellsing
GUV Contact: Helena Lundquist